14.8 C
New York
Friday, April 26, 2024
HomeMarkets
Markets

Morgan Stanley Sees Balance Sheet & Pipeline As More Critical For Johnson & Johnson

By Insider Scoop
0
14
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Related JNJ
CNBC's Stock Pops & Drops From January 20
4 Companies Capturing Social Media Attention On Tuesday Morning
Making Money With Charles Payne: 01/20/15 (Fox Business)

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating and $110.00 price target on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “Guidance confirmed 2015 will be a challenging year highlighted by pharma deceleration. Modest revenue improvement is encouraging, but performance may be tied to pharma pipeline visibility over biosimilar risk and balance sheet optionality. We remain EW.”

Johnson & Johnson closed on Tuesday at $101.29.

Latest Ratings for JNJ

Date Firm Action From To
Jan 2015 Barclays Maintains Equal-weight
Jan 2015 Goldman Sachs Downgrades Neutral Sell
Jan 2015 Jefferies Maintains Hold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,318FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x